未登录
分享
收藏
分享
收藏
分享
收藏
分享
收藏Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial
Xu, Binghe; Zhang, Qingyuan; Sun, Tao; Li, Wei; Teng, Yue'e; Hu, Xichun; Bondarenko, Igor; Adamchuk, Hryhoriy; Zhang, Liangming; Trukhin, Dmytro; Wang, Shusen; Zheng, Hong; Tong, Zhongsheng; Shparyk, Yaroslav; Yang, Futang; Yu, Haoyu; Li, Jing; Wang, Qingyu; Zhu, Jun
分享
收藏
分享
收藏
分享
收藏
分享
收藏Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of HLX14 versus reference denosumab in healthy males: A randomized phase I study
Li, Nanyang; Chu, Nannan; Zhu, Leilei; Wu, Xiaojie; Wei, Qiong; Wang, Jiahui; Hu, Xuhui; Yu, Haoyu; Wang, Qingyu; Yuan, Wei'an; Huang, Kai; Zhang, Jing
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏Comparing the pharmacokinetics, safety, and immunogenicity of HLX02 to US- and EU-approved trastuzumab in healthy Chinese male subjects: A Phase I, randomized, double-blind, parallel-group study
Zhou, Wenjia; Wang, Meng; Yu, Yunli; Wang, Ji; Wu, Yanni; Yang, Guiyu; Yu, Haoyu; Li, Jing; Zhou, Liang; Zhang, Quanying
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏